Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8569257 | 0.81 | CYP1A2 (0.53) | CYP1A2PDGFRBPDGFRAALDH1A1MGAM | |
| SCHEMBL271505 | 0.79 | CYP1A2 (0.53) | CYP1A2PDGFRBPDGFRAALDH1A1MGAM | |
| SCHEMBL8094448 | 0.78 | CYP1A2 (0.57) | CYP1A2PDGFRBPDGFRAALDH1A1MGAM | |
| SCHEMBL5215555 | 0.77 | ALDH1A1 (0.46) | CYP1A2PDGFRBPDGFRAALDH1A1MGAM | |
| SCHEMBL16836313 | 0.76 | TLR8 (0.56) | CYP1A2PDGFRBPDGFRAALDH1A1RAB9A | |
| SCHEMBL24593163 | 0.75 | CYP1A2 (0.53) | CYP1A2PDGFRBPDGFRAALDH1A1MGAM | |
| SCHEMBL271506 | 0.75 | CYP1A2 (0.59) | CYP1A2PDGFRBPDGFRAALDH1A1MGAM | |
| SCHEMBL18814830 | 0.75 | CYP1A2 (0.53) | CYP1A2PDGFRBPDGFRAALDH1A1MGAM | |
| SCHEMBL29105728 | 0.73 | HPGD (0.56) | CYP1A2PDGFRBPDGFRAALDH1A1MGAM | |
| SCHEMBL3820110 | 0.73 | CYP1A2 (0.52) | CYP1A2PDGFRBPDGFRAALDH1A1MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313891-A1 | NEURONAL NICOTINIC AGONISTS AND METHODS OF USE | ABBVIE INC. | 2015-11-05 | — | — | US | disclosed |
| EP-2099795-B1 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBVIE BAHAMAS LTD (BS) | 2015-08-19 | — | — | EP | disclosed |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES | 2015-06-11 | — | — | US | disclosed |
| US-8987453-B2 | Azaadamantane derivatives and methods of use | ABBVIE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2231672-B1 | BIARYL SUBSTITUTED DIAZABICYCLOHEPTANE DERIVATIVES AS nAChR MODULATORS | ABBVIE INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8853241-B2 | Biaryl substituted azabicyclic alkane derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8802693-B1 | Azaadamantane derivatives and methods of use | ABBVIE INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130317055-A1 | NEURONAL NICOTINIC AGONIST AND METHODS OF USE | ABBVIE INC. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2013177494-A1 | AGONISTS OF NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR A7 SUBTYPE FOR USE IN THE TREATMENT OF COGNITIVE SYMPTOMS OF SCHIZOPHRENIA | ABBVIE INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013177498-A1 | AGONISTS OF NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR A7 SUBTYPE FOR USE IN THE TREATMENT OF COGNITIVE SYMPTOMS OF SCHIZOPHRENIA | ABBVIE INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| EP-1198456-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-24 | — | — | EP | disclosed |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-03-21 | — | — | US | disclosed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | disclosed |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-01-31 | — | — | US | disclosed |
| WO-2002006223-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-01-24 | — | — | WO | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001009096-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | CYP1A2 1588/4885PDGFRB 453/4885PDGFRA 343/4885 |
| US-20020028836-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | CYP1A2 1723/4885PDGFRB 4795/4885PDGFRA 4440/4885 |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | CYP1A2 23/4885PDGFRB 842/4885PDGFRA 1156/4885 |
| US-20130317055-A1 | NEURONAL NICOTINIC AGONIST AND METHODS OF USE | CHRNA7, CHRNA2, CHRNA5 | CYP1A2 1790/4885PDGFRB 3727/4885PDGFRA 2823/4885 |
| US-20150313891-A1 | NEURONAL NICOTINIC AGONISTS AND METHODS OF USE | CHRNA7, CHRNA2, CHRNA5 | CYP1A2 1797/4885PDGFRB 3806/4885PDGFRA 2940/4885 |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | GNE, CYP3A5, UGT1A4 | CYP1A2 30/4885PDGFRB 1402/4885PDGFRA 715/4885 |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | CYP1A2 23/4885PDGFRB 842/4885PDGFRA 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.